IL280589A - Preparations for the treatment of graft-versus-host disease - Google Patents
Preparations for the treatment of graft-versus-host diseaseInfo
- Publication number
- IL280589A IL280589A IL280589A IL28058921A IL280589A IL 280589 A IL280589 A IL 280589A IL 280589 A IL280589 A IL 280589A IL 28058921 A IL28058921 A IL 28058921A IL 280589 A IL280589 A IL 280589A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- treatment
- host disease
- versus host
- graft versus
- Prior art date
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 title 1
- 208000024908 graft versus host disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18187409 | 2018-08-05 | ||
| PCT/EP2019/071026 WO2020030593A1 (en) | 2018-08-05 | 2019-08-05 | Compositions for the treatment of graft versus host disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL280589A true IL280589A (en) | 2021-03-25 |
Family
ID=63165229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280589A IL280589A (en) | 2018-08-05 | 2021-02-02 | Preparations for the treatment of graft-versus-host disease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210290741A1 (enExample) |
| EP (1) | EP3829552A1 (enExample) |
| JP (1) | JP2021533150A (enExample) |
| KR (1) | KR20210040395A (enExample) |
| CN (1) | CN112689506A (enExample) |
| AU (1) | AU2019320483A1 (enExample) |
| BR (1) | BR112021002105A2 (enExample) |
| CA (1) | CA3106433A1 (enExample) |
| IL (1) | IL280589A (enExample) |
| MX (1) | MX2021001393A (enExample) |
| WO (1) | WO2020030593A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3136833A1 (en) * | 2019-05-06 | 2020-11-12 | Synthetic Biologics, Inc. | Beta-lactamase compositions for treatment of graft versus host disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2429095T3 (es) | 2005-05-18 | 2013-11-13 | Da Volterra | Aporte colónico de adsorbentes |
| US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
| FI119190B (fi) | 2006-06-21 | 2008-08-29 | Ipsat Therapies Oy | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
| KR101820374B1 (ko) | 2010-02-23 | 2018-01-19 | 다 볼떼라 | 장 내 흡착제의 경구 전달을 위한 제형 |
| FI20105572A0 (fi) | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
| JP6456830B2 (ja) | 2012-09-21 | 2019-01-23 | フェリング ベスローテン フェンノートシャップ | 医薬組成物 |
| BR112016023360B1 (pt) | 2014-04-17 | 2023-03-07 | Synthetic Biologics, Inc | Beta-lactamase e seu uso |
| WO2016057744A1 (en) * | 2014-10-08 | 2016-04-14 | Synthetic Biologics, Inc. | Beta-lactamase formulations and uses thereof |
| FR3027307B1 (fr) | 2014-10-16 | 2016-11-04 | Azurrx Sas | Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| WO2016086161A1 (en) * | 2014-11-25 | 2016-06-02 | Memorial Sloan-Kettering Cancer Center | Intestinal microbiota and gvhd |
-
2019
- 2019-08-05 US US17/263,828 patent/US20210290741A1/en not_active Abandoned
- 2019-08-05 JP JP2021506287A patent/JP2021533150A/ja active Pending
- 2019-08-05 EP EP19746500.8A patent/EP3829552A1/en not_active Withdrawn
- 2019-08-05 BR BR112021002105-1A patent/BR112021002105A2/pt not_active Application Discontinuation
- 2019-08-05 KR KR1020217005467A patent/KR20210040395A/ko not_active Ceased
- 2019-08-05 AU AU2019320483A patent/AU2019320483A1/en not_active Abandoned
- 2019-08-05 CA CA3106433A patent/CA3106433A1/en active Pending
- 2019-08-05 MX MX2021001393A patent/MX2021001393A/es unknown
- 2019-08-05 CN CN201980050483.7A patent/CN112689506A/zh active Pending
- 2019-08-05 WO PCT/EP2019/071026 patent/WO2020030593A1/en not_active Ceased
-
2021
- 2021-02-02 IL IL280589A patent/IL280589A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3829552A1 (en) | 2021-06-09 |
| BR112021002105A2 (pt) | 2021-06-01 |
| CN112689506A (zh) | 2021-04-20 |
| AU2019320483A1 (en) | 2021-02-18 |
| KR20210040395A (ko) | 2021-04-13 |
| JP2021533150A (ja) | 2021-12-02 |
| WO2020030593A1 (en) | 2020-02-13 |
| CA3106433A1 (en) | 2020-02-13 |
| MX2021001393A (es) | 2021-04-12 |
| US20210290741A1 (en) | 2021-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285782A (en) | Compounds, compositions, and methods for treating disease | |
| EP3448874A4 (en) | COMPOSITIONS FOR TREATING A DISEASE | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| ZA202006610B (en) | Compositions for the treatment of skin conditions | |
| ZA202007055B (en) | Compositions for the treatment of skin conditions | |
| IL261774B (en) | Preparations for the treatment of skin problems | |
| HUE061444T2 (hu) | Készítmények a magas vérnyomás kezelésére | |
| IL279609A (en) | Bifunctional compounds for cancer treatment | |
| PL3823655T3 (pl) | Kompozycje do leczenia wulwodynii | |
| ZA202006591B (en) | Compositions for the treatment of hypertension | |
| EP3927375A4 (en) | COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| EP3813872A4 (en) | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | |
| IL280589A (en) | Preparations for the treatment of graft-versus-host disease | |
| IL275384A (en) | Methods and compositions for pre-emptive treatment of graft versus host disease | |
| GB201806663D0 (en) | 2-Oxothiazole compositions for treatment of fibrotic disease | |
| EP3854402C0 (en) | TREATMENT OR PREVENTION OF GRAFT-VERSE-HOST DISEASE | |
| GB201911728D0 (en) | Bacterial composistions for the treatment of disease | |
| HK40045587A (en) | Compositions for the treatment of graft versus host disease | |
| IL263336A (en) | Compounds for the treatment of symphysiolysis | |
| GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies | |
| HK40049516A (en) | Kdm1a inhibitors for the treatment of disease | |
| HK40048442A (en) | Novel medicament for treating inflammatory bowel disease | |
| GB201808964D0 (en) | Treatment of liver disease |